Skip to content

A clinical study to evaluate Vitality Booster Capules for the management of stress and improvement of vitality

Evaluation of efficacy and safety of Vitality Booster Capsules in the management of Stress and Improvement of Vitality in Adults: A prospective, randomised, double-blind, single center, placebo-controlled, interventional study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/10/028656
Enrollment
70
Registered
2020-10-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F430- Acute stress reaction Health Condition 2: N528- Other male erectile dysfunction

Interventions

Intervention1: Vitality Booster Capsules: Vitality Booster Capsules is a nutraceutical product, formulated as a capsule which has Ashwagandha Extract, Proprietary Terminalia Blend and Sarpagandha (2%

Sponsors

Amitojas Wellness Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male subjects aged >= 18 years and 2. Subjects who are experiencing mild to moderate stress; stress score >=15 to 3. Subjects with score 11 to 25 on the Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) at screening visit. 4. Subjects should be in an active stable sexual relationship for the entire duration of study 5. Subjects willing to provide informed written consent.

Exclusion criteria

Exclusion criteria: 1. Subjects with significant medical/surgical condition which requires long-term treatment. 2. Subjects with anatomical abnormalities of the penis. 3. Subjects who are currently being treated with other anti-stress and/or erectile dysfunction drugs. 4. Alcohol or substance abuse 5. Allergy or sensitivity to any of the ingredients in the study treatment 6. Subjects who have participated in other clinical studies during the past 3 months or subjects who intend to participate in other clinical studies parallelly. 7. Subjects with any other illness or health condition which in the opinion/medical judgement of the study investigator makes the subject ineligible to participate in the study.

Design outcomes

Primary

MeasureTime frame
DASS-21 score documented in the CRF at baseline, day 15, and day 30 (values and change from baseline - within the group and between the groups comparisons)Timepoint: baseline, day 15, and day 30

Secondary

MeasureTime frame
Serum Cortisol levels documented in the CRF at baseline, and day 30 (values and change from baseline - within the group and between the groups comparisons)Timepoint: baseline and day 30;Serum Testosterone levels documented in the CRF at baseline, and day 30 (values and change from baseline - within the group and between the groups comparisons)Timepoint: baseline and day 30;36 item Short Form Survey (SF-36) domain scores documented in the CRF at baseline and day 30 (values and change from baseline - within the group and between the groups comparisons)Timepoint: baseline and day 30;International Index of Erectile Function (IIEF) domain scores documented in the CRF at baseline and day 30 (values and change from baseline - within the group and between the groups comparisons)Timepoint: baseline and day 30

Countries

India

Contacts

Public ContactMr Kamal Kammili

Amitojas Wellness Private Limited

cso@amitojas.com8885324455

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026